

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

TRIANGLE PHARMACEUTICALS INC  
Form 8-K  
May 02, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0060  
Expires: May 31, 2000  
Estimated average burden  
hours per response 5.00

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 30, 2002

-----  
TRIANGLE PHARMACEUTICALS, INC.  
-----

(Exact name of registrant as specified in its charter)

DELAWARE

000-21589

56-1930728

-----  
(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

4 University Place, 4611 University Drive, Durham, North Carolina

27707

-----  
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

(919) 493-5980  
-----

-----  
(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure.

On April 30, 2002, Triangle Pharmaceuticals, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits. The following document is incorporated by reference to this Report:

99.1 Press release dated April 30, 2002

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Triangle Pharmaceuticals, Inc.  
-----

(Registrant)

May 1, 2002  
-----

Date

/s/ Robert F. Amundsen, Jr.  
-----

(Signature)

Name: Robert F. Amundsen, Jr.  
Title: Executive Vice President  
& Chief Financial Officer